Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
111M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
107M
-
Shares change
-
+797K
-
Total reported value, excl. options
-
$147M
-
Value change
-
-$1.5M
-
Put/Call ratio
-
0
-
Number of buys
-
55
-
Number of sells
-
-70
-
Price
-
$1.37
Significant Holders of Tango Therapeutics, Inc. - Common Stock, $0.001 par value per share (TNGX) as of Q1 2025
152 filings reported holding TNGX - Tango Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q1 2025.
Tango Therapeutics, Inc. - Common Stock, $0.001 par value per share (TNGX) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 107M shares
of 111M outstanding shares and own 96.6% of the company stock.
Largest 10 shareholders include TRV GP IV, LLC (16.9M shares), TCG Crossover Management, LLC (10.7M shares), EcoR1 Capital, LLC (10.6M shares), Boxer Capital Management, LLC (10.4M shares), Nextech Invest, Ltd. (5.53M shares), GILEAD SCIENCES, INC. (4.85M shares), FARALLON CAPITAL MANAGEMENT LLC (4.61M shares), BlackRock, Inc. (4.03M shares), VANGUARD GROUP INC (3.88M shares), and T. Rowe Price Investment Management, Inc. (3.31M shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.